For healthcare professionals and procurement teams. This is editorial analysis, not patient advice, a product recommendation or a statement of South African availability.
Why it matters
A dedicated device indication can change the framework for a technically demanding intervention without answering every question about comparative outcomes. On 28 October 2026, Abbott announced US Food and Drug Administration approval of the Amplatzer Paraclose PVL Occluder for paravalvular leak closure. [1] For structural-heart teams, the important distinction is between having a purpose-designed option and demonstrating that it outperforms surgery or another catheter-based approach.
This week's development concerns leakage around a surgically implanted replacement valve. It should not be conflated with regurgitation through the prosthesis itself, or with every type of leak following transcatheter valve replacement. The indication and study population must remain central to interpretation.
What happened
The manufacturer's US safety information specifies clinically significant paravalvular leak associated with a surgical aortic or mitral valve prosthesis. [2] The announcement describes a catheter-delivered occluder designed for the gap around a replacement valve and reports FDA approval; this article attributes the regulatory milestone to that official manufacturer release. [1]
The announcement date is not presented as the date on an independently inspected FDA decision letter. Nor does the announcement establish local registration, stocking or funding in South Africa. These distinctions matter when a regulatory headline reaches procurement teams before the complete supporting documentation.
The data
Abbott identifies PARADIGM as the supporting prospective, multicentre, single-arm investigation. Its clinical-data overview reports 200 enrolled patients across 24 centres internationally. [3] This is an interventional study, but it is not a randomised comparison against redo surgery, medical management or another occluder.
The participating Mayo Clinic's study description requires a surgical mechanical or biological valve in the aortic or mitral position and a clinically significant leak graded moderate or higher, associated with heart-failure signs and/or haemolysis requiring recurring transfusions. It also describes preprocedural assessment of a defect suitable for closure with one study device. [4] Those criteria help explain why results cannot automatically be extended to every referral with prosthetic-valve regurgitation.
The UK Health Research Authority's protocol summary describes collection of procedural and discharge data, quality-of-life questionnaires, and follow-up at 30 days, six months and 12 months. [5] These are protocol details, not proof of complete follow-up or a particular treatment effect.
What the design can and cannot establish
A single-arm study can characterise implantation, complications and subsequent clinical course in selected participants. Without a concurrent randomised comparator, it cannot isolate how much an observed improvement would differ from alternative care. Selection, concomitant treatment and follow-up completeness remain relevant to interpretation.
The manufacturer's overview names measures including implant success, intraprocedural mortality, device-related surgery or reintervention, and reduction in leak severity. [3] These measure different aspects of performance. Procedural placement should not be treated as equivalent to durable symptom improvement, freedom from haemolysis or avoidance of later intervention.
This article does not reproduce success percentages, confidence intervals or p-values from promotional graphics without a fully checked numerical source. That is a reporting boundary, not a claim that such data do not exist. A full appraisal should reconcile denominators, assessment times, endpoint definitions and missing observations before drawing a quantitative conclusion.
How the approach works
The target is a channel between the prosthetic valve and surrounding tissue. A catheter carries an occluder to that channel to obstruct unwanted flow around the prosthesis. Abbott describes an oblong design intended to accommodate differing leak shapes. [1] The concept is closure of the surrounding defect, rather than replacement of the functioning prosthesis.
Anatomy remains decisive. The US safety information excludes active infection, a rocking valve, extensive leakage involving more than half the valve perimeter, interfering intracardiac masses, inadequate access and a defect short axis exceeding 5 mm. [2] These are labelled contraindications, not optional preferences or a substitute for the full instructions for use.
Expert commentary in context
In Abbott's announcement, Cleveland Clinic interventional cardiologist Amar Krishnaswamy describes the approval as addressing a treatment gap. [1] That is attributable commentary carried in a manufacturer release, not an independent comparative analysis.
Editorial interpretation: a dedicated indication strengthens the basis for structured evaluation; it does not remove the need to examine selection, durability and complications.
South African professional implications
For local teams, the practical starting point is an evidence review rather than a purchase decision. Our suggested review would separate three questions: whether the referred anatomy fits the intended use, whether the programme can deliver and follow the intervention, and whether the complete evidence justifies adoption in that setting.
Potential adverse events in the US information include embolisation, interference with valve function, stroke, residual or recurrent regurgitation, and new or worsening haemolytic anaemia. [2] A less invasive route should therefore not be described as risk-free. These possibilities belong in professional governance review alongside procedural feasibility.
Procurement appraisal should request the applicable local regulatory documentation, current labelling, available sizes, delivery-system requirements, training arrangements and follow-up support. Any costing exercise should specify its assumptions about imaging, consumables, reintervention and clinical surveillance. No South African price, medical-scheme coverage, SAHPRA status or availability is established here. This report does not assert an Aperture Science distribution or endorsement relationship.
What to watch next
The next useful evidence is a complete, independently appraisable account of PARADIGM, including event adjudication, patient disposition, residual leak and durability. Teams should distinguish study eligibility from final device labelling: similar-looking selection rules may serve different purposes and should not be substituted for one another.
Longer follow-up and appropriately designed comparisons would help clarify which patients benefit most and how catheter closure fits alongside surgical alternatives. Until then, the defensible conclusion is a manufacturer-announced US regulatory advance supported by prospective single-arm evidence, with important limits on comparative inference. This is professional commentary, not patient medical advice.
Source material
References
- Abbott. US FDA approval announcement for Amplatzer Paraclose PVL Occluder. 28 October 2026; checked 2 November 2026.
- Abbott. Amplatzer Paraclose PVL Occluder: US indications, contraindications and potential adverse events. Checked 2 November 2026.
- Abbott. PARADIGM clinical-data overview. Manufacturer summary; checked 2 November 2026.
- Mayo Clinic. PARADIGM: Amplatzer Valvular Plug for PVL Closure; NCT04489823. Study eligibility; checked 2 November 2026.
- UK Health Research Authority. PARADIGM research summary, IRAS 282486. Background protocol information; checked 2 November 2026.




